Patient P-01405

Synthetic patientNBL-101 · Day 118 · 65–74 · F · baseline S14Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Favorable

Inflammatory state

Favorable

Nutritional resilience

Stable

Discontinuation risk

44%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −20% vs expected — Dietary Support Protocol NP-02
Day 44 SC-12 recommended — Supportive Compound SC-12
Day 45 Patient accepted — Started SC-12 in the companion
Day 48 Tolerance state changed — Unstable → Improving
Day 51 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 51 GI symptom burden −23% vs expected — Supportive Compound SC-12
Day 57 Tolerance state changed — Unstable → Improving
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 69 GI symptom burden −22% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 51.

Primary contributors, last 14 days

Treatment adherence+9
Toxicity+5
GI instability-3

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −20%
Supportive Compound SC-12Day 44
Result: symptom burden −23%
GI Support Protocol GI-04Day 60
Result: symptom burden −22%

LIFE OS recommendation

Behavioural Recommendation BR-03

30%

probability of meaningful tolerance improvement

284 similar trajectories
20% showed improvement
median effect visible after 7 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 34/100
- MicrobiomeF. prausnitzii depleted
Autonomic recovery ↑45
- WearableResting HR 73 bpm
- WearableShort sleep window
Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.4 · butyrate capacity 34/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 61 ms
Sleep: 6.6 h
Steps: 9,022
Resting HR: 72 bpm

Daily log: GI score 33, nutritional resilience 56, adherence 64.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01432	61%	S14	GI-04	improved	46
P-01678	47%	S14	GI-04	improved	44
P-01383	46%	S14	NP-02	improved	40
P-01632	46%	S14	GI-04	improved	36
P-01588	41%	S14	GI-04	improved	57
P-01568	40%	S14	GI-04	improved	40
P-01617	40%	S14	SC-12	improved	50
P-01458	39%	S14	GI-04	improved	44
P-01713	39%	S04	GI-04	improved	46
P-01746	39%	S14	NP-02	improved	47
P-01566	38%	S09	GI-04	improved	52
P-01686	38%	S10	GI-04	improved	43